. 2014 Mar 1;24(2):78–82. doi: 10.1089/cap.2013.0099

Table 1.

Baseline Subject Characteristics

	Risperidone	Aripiprazole	Comparison
Male	n=60 (83.3%)	n=56 (80%)	p=0.67^a
Female	n=12 (16.7%)	n=14 (20%)	p=0.67^a
Caucasian	n=56 (77.8%)	n=53 (75.7%)	p=0.84^a
African American	n=6 (8.3%)	n=5 (7.1%)	p=1.00^a
Hispanic	n=1 (1.4%)	n=1 (1.4%)	p=1.00^a
Other race/ethnicity	n=1 (1.4%)	n=1 (1.4%)	p=1.00^a
Autistic disorder	n=40 (55.6%)	n=44 (62.9%)	p=0.40^a
PDD-NOS	n=29 (40.3%)	n=19 (27.1%)	p=0.12^a
Asperger's disorder	n=3 (4.1%)	n=7 (10%)	p=0.21^a
Presence of intellectual disability	n=34 (49%)	n=30 (44%)	p=0.61^a
Age at initiation	8.41±3.59 years	9.74±3.46 years	p=0.03^b
Baseline BMI	19.05±4.90	20.41±5.53	p=0.12^b
Baseline Z-score	0.67±1.44	0.64±1.94	p=0.93^b

^{^a}

Fisher's exact test.

^{^b}

Two tailed t test.

Race/ethnicity data missing in risperidone group (n=7) and aripiprazole group (n=10).

PDD-NOS, pervasive developmental disorder – not otherwise specified; BMI, body mass index.